Get the Stockscreener App
1.90
3.89%
-0.08
MAIA Biotechnology Inc stock is traded at $1.90, with a volume of 130.58K.
It is down -3.89% in the last 24 hours and down -20.04% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.98
Open:
$2.01
24h Volume:
130.58K
Relative Volume:
0.41
Market Cap:
$51.79M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.3768
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
+1.22%
1M Performance:
-20.04%
6M Performance:
-25.08%
1Y Performance:
+34.01%
1-Day Range:
$1.88
$2.02
1-Week Range:
$1.83
$2.30
52-Week Range:
$1.24
$5.99
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.903 | 51.79M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.86 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.92 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.00 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.86 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology Announces Efficacy Updates for THIO-101 Trial in Advanced Non-Small Cell Lung Cancer - Defense World
MAIA Biotechnology Amends Employment Agreements with Executive Officers - Defense World
MAIA Biotech executives receive salary hikes and new terms - MSN
MAIA Biotech executives receive salary hikes and new terms By Investing.com - Investing.com UK
MAIA Biotechnology Updates Executive Compensation Packages - TipRanks
MAIA Biotechnology Inc (MAIA) can make a big difference with a little luck - SETE News
Investing in MAIA Biotechnology Inc (MAIA) Is Getting More Attractive - Knox Daily
MAIA Biotechnology Reports Promising Phase 2 Trial Results - TipRanks
MAIA Biotechnology reports promising THIO trial results for NSCLC By Investing.com - Investing.com South Africa
MAIA Biotechnology announces updated data from THIO-101 trial - MSN
MAIA Stock on the Rise: A Promising Investment - The InvestChronicle
Breaking down MAIA’s current quarter earnings estimates - US Post News
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer - BioSpace
MAIA Biotechnology reports promising THIO trial results for NSCLC - Investing.com India
MAIA Biotechnology, Inc. Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer - Marketscreener.com
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 0.5% Higher – What’s Next? - Defense World
MAIA Biotechnology, BeiGene announce clinical supply agreement - The Cancer Letter
Geode Capital Management LLC Grows Position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) - Defense World
MAIA Biotech to Present THIO Cancer Treatment Pipeline at Biotech Showcase 2025 - StockTitan
MAIA Biotechnology to Present at Biotech Showcase 2025 - Yahoo Finance
MAIA Biotechnology Shares Rise After Supply Agreement With BeiGene - MarketWatch
MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications - BioSpace
MAIA Biotech partners with BeiGene for cancer trials - Investing.com
MAIA Biotechnology Directors Show Strong Confidence with $573K Personal Investment in Private Placement - StockTitan
MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings - Business Wire
Big Moves at MAIA Biotechnology! Insider Buying and Market Insights - Clinique Bio
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas - Business Wire
Investing Insights: MAIA Biotechnology’s Promising Moves - Clinique Bio
Stan Smith Acquires 25,000 Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Stock - MarketBeat
Maia Biotechnology director Stan Smith acquires $46,800 in stock - Investing.com India
Maia Biotechnology director Stan Smith acquires $46,800 in stock By Investing.com - Investing.com South Africa
Maia Biotechnology director Ramiro Guerrero buys $99,998 in stock - Investing.com
Maia Biotechnology director Ramiro Guerrero buys $99,998 in stock By Investing.com - Investing.com UK
MAIA Biotechnology, Inc. announced that it expects to receive $0.949785 million in funding - Marketscreener.com
MAIA Biotechnology announces $950,000 private placement - MSN
MAIA Biotechnology Secures $950K Private Placement to Advance THIO Clinical Trials - StockTitan
MAIA Biotechnology Announces Private Placement of Approximately $950,000 - Business Wire
MAIA Biotech expands phase 2 trial for lung cancer treatment By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer - XM
MAIA Biotech expands phase 2 trial for lung cancer treatment - Investing.com
Diamond Equity Forecasts MAIA Biotechnology Q1 Earnings - Defense World
Analysts Set Expectations for MAIA Biotechnology Q1 Earnings - MarketBeat
MAIA Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
THIO Combo Shows Enduring Activity in Advanced Non–Small Cell Lung Cancer - Cancer Network
MAIA Biotechnology Inc (MAIA): A New Perspective - Stocks Register
MAIA Biotechnology Reveals Promising Phase 2 Trial Results - TipRanks
MAIAMAIA Biotechnology, Inc. Latest Stock News & Market Updates - StockTitan
MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement - BioSpace
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Yahoo Finance
Maia Biotechnology director Stan Smith buys shares worth $250,999 - Investing.com
Maia Biotechnology director Stan Smith buys shares worth $250,999 By Investing.com - Investing.com Canada
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
MAIA Biotechnology Inc Stock (MAIA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Guerrero Ramiro | Director |
Dec 13 '24 |
Buy |
1.87 |
53,418 |
99,998 |
514,970 |
| Luput Cristian | Director |
Nov 01 '24 |
Buy |
2.51 |
22,133 |
55,554 |
389,483 |
| CHAOUKI STEVEN M | Director |
Nov 01 '24 |
Buy |
2.51 |
22,133 |
55,554 |
111,024 |
| Guerrero Ramiro | Director |
Nov 01 '24 |
Buy |
2.51 |
88,534 |
222,220 |
408,134 |
| Smith Stan | Director |
Nov 01 '24 |
Buy |
2.51 |
100,000 |
251,000 |
957,568 |
| Louie Ngar Yee | Director |
Apr 25 '24 |
Buy |
2.03 |
19,665 |
39,920 |
1,167,189 |
| Smith Stan | Director |
Apr 25 '24 |
Buy |
2.03 |
147,492 |
299,409 |
1,005,060 |
| CHAOUKI STEVEN M | Director |
Mar 14 '24 |
Buy |
1.17 |
34,641 |
40,530 |
88,891 |
| Smith Stan | Director |
Mar 14 '24 |
Buy |
1.17 |
170,940 |
200,000 |
857,568 |
| Louie Ngar Yee | Director |
Mar 14 '24 |
Buy |
1.17 |
170,940 |
200,000 |
1,147,524 |
0.51%
Cap:
|
Volume (24h):